Navigation Links
Therabron Therapeutics Receives Accelerated Second Tranche from Series B Financing and Expands Investor Syndicate

ROCKVILLE, Md., Nov. 9, 2015 /PRNewswire/ -- Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that the Company has received an accelerated second tranche from its previously announced Series B financing and expanded its investor syndicate with gross proceeds of up to $6.75 million. Brace Pharma Capital led the financing.

"The last year has been important for Therabron as we are now moving toward the end of patient enrollment in the phase 2 clinical trial for CG100 and have advanced our scientific understanding of the broad potential of our recombinant human secretoglobin platform across several respiratory disorders," said Dr. Thomas F. Miller, President of Therabron. "We are thrilled that our investors have continued confidence in Therabron and endorse our strategy to expand the scope of development of our proprietary platform."

The Company's lead product candidate, CG100, is currently being investigated in a phase 2 clinical trial for the prevention of chronic respiratory morbidities (CRM) in preterm infants. Therabron anticipates enrollment for this study to be completed by the end of 2015.

Therabron is also advancing other promising programs with the goal of opening a second IND in 2016 targeting patients in the Pediatric Intensive Care Unit (PICU) where pathogen infections, such as influenza and respiratory syncytial virus (RSV) can lead to respiratory failure.  Additional lead optimization activities will also progress for newly created analogues of recombinant human CC10 proteins intended to target ambulatory respiratory disorders, such as chronic obstructive pulmonary disease (COPD).

About Therabron Therapeutics, Inc.

Therabron Therapeutics, Inc. is a clinical-stage biotechnology company, founded in 2007 and located in Rockville, MD.  Therabron is focused on the advancement of respiratory therapeutics with disease-modifying potential. The Company's product candidates aim to restore the natural immune balance in the lungs of patients with respiratory disorders through the administration of recombinant human CC10 proteins. The family of CC10 proteins, also known as secretoglobins, has the potential to change the course of acute and chronic respiratory diseases, representing large markets into which few truly novel drugs have been introduced. Therabron's product candidates have the potential to be first-in-class, disease-modifying, breakthrough biologic therapeutics. For additional information, please visit


SOURCE Therabron Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program
2. Clinical Data Featuring Trovagenes Precision Cancer Monitoring Platform to be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update
4. Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022 - Reportlinker Review
5. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015
6. Relmada Therapeutics Responds to 13D Filing by Laidlaw
7. Envisia Therapeutics Selected To Present During Drug Delivery Company Showcase At 2015 Ophthalmalogy Innovation Summit
8. Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy
9. Viking Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update
10. Global Antiviral Therapeutics Technologies, Markets and Companies Analysis Report 2015-2024
11. Johnson & Johnson Announces Agreement To Acquire Novira Therapeutics, Inc.
Post Your Comments:
(Date:7/2/2020)... ... ..., the fitness industry’s leading tech company specializing in all-in-one business software for ... during the months of May and June. This announcement highlights the growing demand for ... giants like 24 Hour Fitness and Gold’s Gym are unsafe ...
(Date:7/1/2020)... ... ... Dexur’s analysis of medicare claims of hospitals within a 25-mile radius of Cleveland, ... Center , and Lutheran Hospital had the best value outcomes ... a patient’s episode of care from the date of admission for 90 days and ...
(Date:6/28/2020)... ... June 28, 2020 , ... ... New studies substantiate the effectiveness of oral-care probiotics to maximize teeth and ... While the science behind both is simple – utilizing naturally occurring positive bacteria ...
Breaking Medicine Technology:
(Date:7/7/2020)... PORTLAND, Ore. (PRWEB) , ... July 07, 2020 ... ... and a unique one or two head design to efficiently sanitize large surfaces ... , is now available to support sales in that region. , In ...
(Date:7/2/2020)... ... 02, 2020 , ... Dr. Christine Blaine has earned a stellar ... offices located in Staten Island, Huntington and NYC, NY. Her former Manhattan clinic, ... suite at The Parlor NYC at 160 Madison Avenue. Blaine Plastic Surgery ...
(Date:7/1/2020)... ... July 01, 2020 , ... ABSTRAX, an ... officially released its new terpene infused product line including custom rolling papers, ... enjoy cannabis terpene profiles and flavors worldwide. , “We’ve made it easier than ...
(Date:6/28/2020)... ... June 26, 2020 , ... Medisend College ... high-quality, intensive education and training that prepares graduates for professional careers as field ... of the Board of Trustees. , Ms. Williams currently serves as Associate Vice ...
(Date:6/28/2020)... ... June 27, 2020 , ... The FSHD Society announced ... conference in the organization’s history. The online conference takes the place of FSHD ... cancelled this year due to COVID-19. Nearly 300 individuals and families living with ...
Breaking Medicine News(10 mins):